(2,5-Dioxopyrrolidin-3-yl) 2-methylhept-4-ynoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2,5-Dioxopyrrolidin-3-yl) 2-methylhept-4-ynoate
• 英文别名: (2,5-dioxopyrrolidin-3-yl) 2-methylhept-4-ynoate
• 化学式: C₁₂H₁₅NO₄
• 分子量: 237.25
• InChiKey: NFTILJLQKYNJDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  72.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS<br/>[FR] COMPOSITIONS DE DIFLUOROLACTAME DESTINÉES À DES MALADIES ET DES AFFECTIONS OSSEUSES MÉDIÉES PAR EP4
  申请人：CAYMAN CHEMICAL CO INC

  公开号：WO2014015246A1

  公开（公告）日：2014-01-23

  Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.

  披露的是通过给予公式(I)化合物的组合物和方法来治疗骨质疏松症、骨折、骨丢失以及增加骨密度，其中组合物包含公式(I)的化合物和药用可接受的载体，其中L1、L2、L4、R1、R4、R5、R6和s按说明书定义。
• DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS
  申请人：Cayman Chemical Company, Incorporated

  公开号：EP2875022A1

  公开（公告）日：2015-05-27
• DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS
  申请人：Cayman Chemical Company, Incorporated

  公开号：EP2874620A1

  公开（公告）日：2015-05-27
• METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG
  申请人：Cayman Chemical Company, Inc.

  公开号：EP2970234A2

  公开（公告）日：2016-01-20
• [EN] DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS<br/>[FR] COMPOSÉS DE DIFLUOROLACTAME COMME AGONISTES SÉLECTIFS DU RÉCEPTEUR EP4, DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES ET D'AFFECTIONS MÉDIÉES PAR EP4
  申请人：CAYMAN CHEMICAL CO INC

  公开号：WO2014015247A1

  公开（公告）日：2014-01-23

  Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.